• 29 Apr 2026
• Admin
• News Article

Votoplam Shows Promising Disease-Slowing Signals in Huntington’s Disease

For decades, Huntington’s disease research has faced a brutal reality: no approved therapies slow disease progression. That’s why the latest update from PTC Therapeutics, Inc. deserves attention.

The company has reported positive 24-month interim results from its PIVOT-HD long-term extension study, showing dose-dependent slowing of disease progression with votoplam.

The Headline Result: Slowing Disease Progression

Let’s get straight to what matters.

Key findings (Stage 2 patients):

• 52% slowing of disease progression at 10 mg dose
• 28% slowing at 5 mg dose
• Measured using the Composite Unified Huntington’s Disease Rating Scale (cUHDRS)

These results were benchmarked against a matched natural history cohort, not just placebo. That distinction matters—it reflects how patients typically decline in the real world. Matthew B. Klein, CEO of PTC, summed it up: The dose-dependent slowing gives confidence in votoplam’s potential to deliver meaningful long-term impact.

Understanding the Study Design

The data comes from the PIVOT-HD clinical program, which includes both a core study and a long-term extension.

Original PIVOT-HD study:

• 12-month, placebo-controlled trial
• Two dose levels: 5 mg and 10 mg
• Included Stage 2 and Stage 3 patients
• Met primary endpoint: reduction in Huntingtin (HTT) protein at 12 weeks

Long-term extension (current data):

• All participants receive votoplam
• Previously treated patients stay on same dose
• Placebo patients re-randomized to active doses
• Blinded study design maintained

The goal: assess long-term safety and efficacy over 24 months and beyond.

Biomarker Signals Strengthen the Case

Beyond clinical scores, the study tracked biological markers of disease progression.

Key biomarker insights:

• Sustained dose-dependent lowering of HTT protein
• No increase in neurofilament light chain (NfL) levels
• NfL levels remained below baseline at 24 months

Why this matters:

• NfL typically rises as neurodegeneration worsens
• Stabilization (or reduction) suggests potential disease-modifying effect

Safety Profile: Still Holding Up

Long-term safety is often where promising therapies fail. So far, votoplam is holding steady:

• Favorable safety profile maintained at 24 months
• No new major safety concerns reported
• Consistent across both dose levels and disease stages

This is critical for a chronic, progressive condition requiring long-term treatment.

What About Stage 3 Patients?

The signal is less definitive, but still encouraging.

• Early indications of slowing progression at 24 months
• Not as strong or consistent as Stage 2 results
• Suggests earlier intervention may deliver greater benefit

This aligns with broader trends in neurodegenerative diseases: earlier treatment = better outcomes.

How Votoplam Works?

Votoplam is not a conventional therapy. It targets the disease at the genetic level.

Mechanism of action:

• A small molecule splicing modifier
• Induces inclusion of a pseudoexon in HTT mRNA
• Triggers degradation of Huntingtin (HTT) mRNA
• Leads to reduced production of toxic HTT protein

In simple terms: it cuts the problem upstream, before toxic protein accumulates.

The Bigger Development Milestone

This data has already triggered the next step. Novartis has initiated the global Phase 3 INVEST-HD trial.

Phase 3 study design:

• ~770 early-stage patients
• Randomized 3:2 (votoplam 10 mg vs placebo)
• 36-month study duration
• Primary endpoint: change in cUHDRS

Novartis is now leading:

• Development
• Manufacturing
• Commercialization

This transition signals strong confidence in the asset.

The Unmet Need: Why This Matters?

Huntington's disease is:

• Fatal and hereditary
• Typically onset in 30s–40s
• Progressive across motor, cognitive, and behavioral domains

And critically:

• No approved therapies slow or stop progression

Current treatments only manage symptoms—not the disease itself.

Final Take

Votoplam is starting to check important boxes:

• Clinical signal: Meaningful slowing in Stage 2 patients
• Biological validation: HTT reduction + stable NfL
• Safety: Consistent over 24 months
• Momentum: Phase 3 already underway

But there are still open questions:

• Will Phase 3 replicate these results at scale?
• Can benefits extend meaningfully to later-stage patients?
• How durable are these effects beyond 24 months?

For now, this is one of the more credible attempts at a disease-modifying therapy in Huntington’s. And in a field where progress has been painfully slow, that alone makes it worth watching closely.